Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Avapritinib |
Trade Name | Ayvakit |
Synonyms | BLU-285 |
Drug Descriptions |
Ayvakit (avapritinib) is a selective inhibitor of PDGFRA D842V and KIT exon 17 mutants, including KIT D816V, potentially resulting in decreased tumor growth (PMID: 30274985). Ayvakit (avapritinib) is FDA approved for use in patients with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including D842V, and in patients with advanced systemic mastocytosis (FDA.gov). |
DrugClasses | KIT Inhibitor 57 PDGFR-alpha Inhibitor 9 |
CAS Registry Number | 1703793-34-3 |
NCIT ID | C123827 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Adavosertib + Avapritinib | Adavosertib Avapritinib | 2 | 0 |
Avapritinib | Avapritinib | 69 | 7 |
Avapritinib + Decitabine | Avapritinib Decitabine | 0 | 1 |
Avapritinib + Decitabine and Cedazuridine | Avapritinib Decitabine and Cedazuridine | 0 | 1 |
Avapritinib + Midazolam | Avapritinib Midazolam | 0 | 1 |